Catabasis shares 1st triglyceride data for drug conjugate
This article was originally published in Scrip
Preliminary data from a Phase I clinical trial for the Catabasis Pharmaceuticals hypertriglyceridemia drug CAT-2003 show significant reductions in fasting and post-prandial triglyceride levels in both healthy volunteers and patients with mild lipid elevations.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.